• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cell & Gene Therapy Fueled Large Surge in Clinical Holds Last Year

Cell & Gene Therapy Fueled Large Surge in Clinical Holds Last Year

March 7, 2022

FDA clinical trial holds saw a sharp increase in 2021, propelled in large part by holds on cell and gene therapy trials.

Last year’s spike was large enough to put the amount of clinical holds at double the historical average, according to an analysis of the past 12 years by investment banking firm Jefferies. One reason for the development, according to Jefferies equity analyst Michael Yee, is increased clinical trial activity in the cell and gene therapy space.

Cell and gene therapy trials accounted for approximately 40 percent of all clinical holds last year despite comprising far less than 40 percent of all trials, “suggest[ing] there are technical and safety questions that still need to be worked through” for such products, Yee wrote.

The analysis notes that 50 to 60 percent of clinical holds end up being lifted, with oncology and hematology seeing the highest rates of resumption and neurology and infectious disease seeing the lowest.

Overall, oncology has been responsible for half of all clinical holds since 2010. Yee noted that while cancer trials comprised a majority of holds between 2014 and 2019, last year’s surge (which extended partly into 2020) was fueled by other therapeutic areas that have seen development booms, including gene therapy, gene editing and neurology.

“This could be because of increased new drug development outside of oncology, but we also wonder whether developers are taking riskier approaches with nononcology drugs as well,” Yee said.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing